Japanese Journal of Clinical Oncology 31:297-298 (2001)
© 2001 Foundation for Promotion of Cancer Research
Editorial |
Ablation of Hepatocellular Carcinoma
Third Department of Surgery, Nihon University, Tokyo and Department of Hepato-Biliary-Pancreatic Surgery, The University of Tokyo, Tokyo, Japan
Hepatocellular carcinoma (HCC) ranks third in frequency among cancers in Japan and its rising incidence is a serious problem in more developed countries. Although there is no doubt that early diagnosis and treatment improve survival (1), the criteria by which a specific treatment is selected as the first-line option remain to be established. Surgery offers the chance of potential cure, either by curative hepatic resection or transplantation. However, resection is applied only to patients with good hepatic reserve and localized tumors: the resectability rate in Japan is around 30%. Alternatively, local ablation therapy has gained a clinical position in treating small HCC (2).
Ablation therapy, most
REFERENCES